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Abstract: The use of nanoparticles has contributed to many advances due to their important
properties such as, size, shape or biocompatibility. The use of nanotechnology in medicine has
great potential, especially in medical microbiology. Promising data show the possibility of shaping
immune responses and fighting severe infections using synthetic materials. Different studies have
suggested that the addition of synthetic nanoparticles in vaccines and immunotherapy will have a
great impact on public health. On the other hand, antibiotic resistance is one of the major concerns
worldwide; a recent report of the World Health Organization (WHO) states that antibiotic resistance
could cause 300 million deaths by 2050. Nanomedicine offers an innovative tool for combating
the high rates of resistance that we are fighting nowadays, by the development of both alternative
therapeutic and prophylaxis approaches and also novel diagnosis methods. Early detection of
infectious diseases is the key to a successful treatment and the new developed applications based
on nanotechnology offer an increased sensibility and efficiency of the diagnosis. The aim of this
review is to reveal and discuss the main advances made on the science of nanomaterials for the
prevention, diagnosis and treatment of infectious diseases. Highlighting innovative approaches
utilized to: (i) increasing the efficiency of vaccines; (ii) obtaining shuttle systems that require lower
antibiotic concentrations; (iii) developing coating devices that inhibit microbial colonization and
biofilm formation.
Keywords: nanoparticles; vaccines; microbiology diagnosis; biofilm; antibiotic resistance
1. Introduction
In 1959, Richard Feynman described a process that allows one to individually manipulate atoms
and molecules throughout high precision instruments. This system could be applied to design and
build systems at nanoscale level, atom by atom [1,2] and its applications in many areas of wide interest
such as health, industry, pharmacy, etc., seem to be unlimited. In 1981 the engineer Eric Drexler,
inspired by Feynman’s speech, published the article entitled “Molecular engineering: An approach to
the development of the general capabilities for molecular manipulation” in which he described more
in detail what Feynman have previously described [3]. The term “nanotechnology” was first applied
by Drexler in 1986 [4] and it has been used for this area of expertise since.
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Nanotechnology refers to the area of the knowledge that designs and produces structures,
devices and systems by manipulating atoms and molecules at the nanoscale level [5]. Nanoparticles
are microscopic particles smaller than 100 nanometers [6]. Due to their small size, nanoparticles
have unusual properties which make their use in nanomedicine advantageous [7]. Nowadays most
nanoparticles are obtained from transition metals, silicon, carbon and metal oxides.
Nanobiotechnology is the area of nanotechnology focused on the biological field. Nanoparticles
utilized in biology are grouped into three categories: organic, inorganic and mixed (organic/inorganic) [8].
In recent years, many nanoparticles have been developed for diverse applications in medicine, including
infectious diseases. The development of nanoparticles in this area has been beneficial due to their
selective antimicrobial effect with low toxicity against the host and their ability to place their action on
specific targets.
Shuttle systems are commonly used for the delivery and stabilization of bioactive drugs and
antimicrobial molecules, ensuring not just their specificity but also controlled release [8]. Coating
medical devices is of a great advantage in the infectious disease field, e.g., nanomodified surfaces and
devices proved to be very efficient to reduce microbial attachment and biofilm formation [9,10].
The use of nanomaterials as biosensors has currently a vast impact and a fast development in the
usage of smart nanobiomaterials. Biosensors are accurate and offer a cost effective approach for the
detection of pathogenic infectious agents in natural environment, food but also clinical specimens [11].
Nanondiagnostics was first introduced by Mirkin et al. [12] in 1996 where the authors published the
use of gold (Au)-nanoparticles to allow anthrax detection [13].
The aim of this review is to highlight and discuss the recent progress and applications of
nanotechnology in the medical field (nanomedicine) focusing on the prevention, diagnosis and
treatment of infectious diseases.
2. Nanoparticles and Vaccines
Traditional vaccines have been developed using live attenuated organisms (cellular vaccines) or
inactivated toxins or proteins (acellular vaccines). Recently, the development of synthetic peptide-based
vaccines has shown many advantages compared with traditional vaccines, such as better safety and/or
conservation. However, the peptide-based vaccines generate a weaker immune response, and the
inclusion of adjuvants and/or the use of vaccine delivery systems is highly needed [14]. Antibacterial
vaccines, both cellular and acellular, are still considered the most cost effective intervention against
bacterial infections. Implementation of vaccine schedules has decreased worldwide the morbidity
and mortality caused by infectious diseases such as diphtheria, pneumococcal and pertussis diseases.
However, the treatment and prevention of other common bacterial infections, including but not limited
to Staphylococcus aureus, Helicobacter pylori, Shigella spp. or Escherichia coli is still not possible [15].
Nanoparticles have several applications in nanobiomedicine, especially in the field of vaccine
production where they can be applied as efficient delivery systems. Their particular nature increases
cross-presentation of the peptide [16] and it also plays an important role in the activity of antigen
presentation cells (APC) [16,17]. The main application of synthetic nanoparticles in immune
engineering relies on the modulation of APC, by encapsulating or releasing molecules that promote
dendritic cell activation, triggering particle-specific immune recognition and thus, antigen processing.
Nanoparticles can further act as co-adjuvants, stimulating the proper pro- or anti-immunity pathways.
This immuno-stimulation can be achieved by encapsulation of various compounds and/or according
to their structure or composition [17]. In addition, hypersensitivity produced by the nanoparticles used
can be ameliorated by slowing the rate of infusion of the delivery nanovaccine system, by modulating
their shape and size, or by patient premedication [18].
Nanomaterials may have intrinsic immunomodulatory functions, acting as adjuvants or
immune potentiators [17]. According to the nanomaterial composition [19], the vaccine-associated
nanoparticles [20] could be classified in different types (Table 1).
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(i) Polymers, divided in turn into nanoparticles containing synthetic polymers, such as
poly(D,L-lactic-co-glycolic acid)(PLGA) [21], polyethylene glycol (PGE) [22] or polyester
bio-beads [23], and natural polymers based on polysaccharides such as alginate [24], inulin [25]
or chitosan [26]. Synthetic and natural polymers have been used to synthesize hydrogel
nanoparticles, which have favorable properties including but not limited to flexible mesh size,
large surface area for multivalent conjugation, high water content, and high antigen loading
capacity [27];
(ii) Liposomes, which are biodegradable and non-toxic phospholipids. They encapsulate antigens
and incorporate viral envelope glycoproteins to form virosomes. The combination of a modified
cationic liposome and a cationic polymer (such as protamine)-condensed DNA is called
liposome-polycation-DNA nanoparticles (LPD). They are commonly used as adjuvant delivery
system in DNA vaccine studies [28];
(iii) Nanosized emulsions are those nanoparticles that can exist as oil-in-water or water-in-oil form.
Emulsions can carry antigens inside their core to increase the efficiency of vaccine delivery or
they can also be simply mixed with antigen [20];
(iv) Inorganic nanoparticles are non-biodegradable, they have rigid structure and controllable
synthesis. Silica-based nanoparticles (SiNPs) offer the advantage of biocompatibility and have
excellent properties as nanocarriers. SiNPs particles such as mesoporous silica nanoparticles
(MSNs) could potentially become high-efficient, controlled-release nanocarriers in future vaccine
formulations [20].
(v) Immuno-stimulating complexes (ISCOM). They are composed of supra-molecular structures of
the adjuvant Quil A and immunizing peptides, which allows selective incorporation of viral
envelope proteins by hydrophobic interaction [29].
(vi) Virus-like particles (VLP) are optimized for interaction with the immune system, avoiding the
infectious components. They can induce potent immune responses, even in the absence of
adjuvant [30]. VLP based vaccines have been the first nanoparticle class to reach market [31],
found for example under the following Engerix®, RECOMBIVAX®HB against to HBV [32].
(vii) Self-assembling systems emerged as a consequence of an attempt to drive higher levels of
protein, and consequently better immunological properties. A variety of natural proteins can be
self-assembled into nanoparticles, conferring highly symmetric, stable and organized structure [32].
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Table 1. Most representative vaccine applications based on nanotechnology.
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Table 1. Cont.
Type of Nanoparticles Based on Main Characteristic Use Representative Uses Ref.
Liposomes
LPD
phospholipids Biodegradable & nontoxicencapsulate Ag and form virosomes
adjuvant
P. malarie [40]
Influenza Virus (INFLEXAL® V) [62]
HAV (Epaxal®)
HIV [63]
ICMV adjuvant carrier P. vivax [40]
Emulsions Oil-in-water/water-in-oil
MF59™
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Table 1. Cont.
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Ag: antigens; AuNP: Gold nanoparticles; GNP: gold glyco-NPs; HAV: Hepatitis A Virus; HEV: Hepatitis E Virus; HSV: Herpes Simple Virus; ICMVs: Liposomes modified with
maleimide synthesized into interbilayer-crosslinked multilamellar vesicles; ISCOM: Immuno-stimulating complex; JEV: Japanese encephalitis virus; LPD: liposome-polycation-DNA
nanoparticles; MSNs: mesoporous silica nanoparticles; MVP: vault protein; NDV: Newcastle disease virus; PGE: poly(ethylene glycol); PLG: poly(D,L-lactide-co-glycolide);
PLGA: poly(D,L-lactic-coglycolic acid); SAPN: self-assembling peptide nanoparticles; SARS-CoV: Severe acute respiratory syndrome-associated coronavirus; VEB: Virus Epstein-Bar;
VZV: Varizela Zoster Virus; WNV: West Nile virus.
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3. Microbial Detection by Using Nanoparticles
The emergence of infections together with the fast evolution of drug-resistant bacteria
(superbugs), are triggering the increased ineffectiveness of actual therapies used to treat infectious
diseases [94]. Clinical microbiology laboratories still use the conventional phenotypic methods for the
identification of bacteria and novel mechanisms of resistance. Nowadays laboratories are supported
by molecular biology techniques, such as those based on 16S rRNA sequencing, but also various
advanced physico-chemical analysis. Matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF MS) is becoming a reliable method for microbial identification in several
hospitals, due to their speed, accuracy and cost effectiveness [95]. For the design of an optimal
diagnosis method, some parameters should be considered: this would be a cost-effective, portable,
and point of source-detection system which would be also highly reliable, sensitive, and accurate [96].
The desirable method also should be able to detect multiple pathogens in one single run.
A number of nanotechnology-based materials have been studied with the purpose of controlling
and preventing infectious diseases [97]. The physical and chemical properties of nanoparticles allow
accurate, rapid, sensitive, and cost-efficient diagnostics [94]. Antibody-based diagnoses such as
those utilizing Fluorescent Silica Nanoparticles (FSNPs) have been developed in order to detect
Mycobacterium tuberculosis complex (MTB) within 4 h [98]. Incorporating europium [Eu(III)] polymeric
nanoparticles have been successfully for the detection of anthrax antibodies by using fluorescence
enzyme linked immunosorbent assay (ELISA) [94]. A combination of positive di-electrophoresis and
aptamer-FSNPs label has been developed as a rapid and sensitive method for detection of S. aureus [99].
Wang and Kang [100] have developed recently, a method for detection of Salmonella typhimurium based
on a single-stranded DNA aptamers along with silica fluorescence nanoparticles.
Liposomes can recognize target toxins, and therefore they can be used for toxin detection.
Liposomes labelled with fluorescent markers (such as rhodamine dyes) can be incorporated into
sandwich fluoro-immunoassay on antibody-coated microtiter plates in order to detect toxins [101].
Ahn-Yoon et al [102], had used this method to detect cholera toxin within a limit of detection of
10 fg/mL and in only 20 min [102]. A similar assay was developed to detect botulinum toxin (BT) on
a nitrocellulose membrane strip by using tri-sialo-ganglioside GT1b-liposomes, which is a receptor
for BT [103].
Quantum dots (QDs) are special nanocrystalline semiconductors [94] composed of materials
such as ZnS, ZnSe, CdS, CdSe, CdTe and InP, among others [104]. QDs show strong resistance to
photobleaching and chemical degradation, as well as significant photostability and high quantum
yield [105]. These characteristics make them suitable for sensitive image acquisition and signal
amplification in real time [94]. The applications of QDs in nanobiomedicine are diverse, varying from
fluorescent probes, biosensors to therapeutics agents [104]. Numerous methods have been developed
for creating hydrophilic QDs [106]. Among QDs’ bioapplications, it is important to highlight, multiplex
detection of analytes based in single molecule detection. QD-based nanosensors are an example of a
highly sensitive, extremely low cost-per-sample technique, that ensures short analysis time and it has
the potential to be applied for rapid detection of viral and bacterial proteins, with enhanced sensitivity
and specificity over conventional organic fluorophores [104].
In 2010, Zhang and Hu [107] developed a multiplex assay for the detection of HIV-1 and HIV-2.
This single-QD-based nano-sensor showed an extremely low sample consumption, high sensitivity
and short analysis time. These results have shown the many advantages of this method to be applied
for rapid point-of-care testing, gene expression studies, high-throughput screening, and clinical
diagnostics. Six years later, Zhang et al. [108] designed an efficient immunosensor-based technique
for screening and isolating Salmonella sp. with a detection limit of 10 cell/mL. The aforementioned
fluorescent nanobioprobes made on a specially designed cellulose-based swab could be applied in a
large number of samples related to public health surveillance to visually detect and directly isolate
pathogens in situ.
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In 2007, Klostranec et al. [109] reported the use of QDs with microfluidics for the obtention of
bio-imaging signals, improving the high sensitivity for their use in diagnosis. QD-antibody conjugates
has also been successfully used in fluoro-immunoassays for the detection of staphylococcal enterotoxin
B [110], syncytial respiratory virus [111] or hepatovirus, and HVB, HCV, and HIV viruses [112].
Ebrahim et al. [113] have been able to synthesize CdTe-QDs conjugated with concanavalin A for the
detection of lipopolysaccharide (LPS) produced by Serratia marcescens with a detection range from 10
to 106 colony forming units/mL (CFU/mL) at pH 7.
Detection systems based on noble metal nanoparticles (Table 2), particularly Au and Ag, have been
widely studied due to their unique optical and physicochemical properties [114] and they are known
as surface plasmon resonance (SPR) [94]. Their nano-size scale and their optical/physicochemical
properties have been used for selective and specific identification of DNA/RNA sequences, proteins, or
small analytes associated with the presence of infection and various pathogens. Their detection relies on
colorimetric assays, fluorescence, mass spectrometry, electrochemical, and scattering approaches [95].
In 2005, Duan et al. [115], reported the usage of immune-gold silver staining with Au-nanoparticles as
a very sensitive method for the detection of single molecules and its application for the detection of
HCV and HBV.
Magnetic nanoparticles (MNPs) have nanoscale sizes, which mimic the size of molecules in
nature, and they harbor favorable characteristics for their use in nano-biomedicine, such as imaging
and therapy [105]. Surface modification of MNPs with recognition moieties, for instance, antibodies,
antibiotics, and carbohydrate, enables their use for bacterial detection.
These recognition moieties help to detect the bacteria selectively and at low concentrations [94,116].
The super-paramagnetic property provides MNPS with a promising and sophisticated platform for
in vivo detection techniques and have the potential to make microbiological diagnostics become much
easier and more worthy [116,117] (Table 2). MNPs can be classified as metal, alloys or oxides, and are
generally based on elements such as Fe, Co, Ni, or Mn, among others [105]. Iron oxide nanoparticles
(IONPs) are the most studied and are composed of magnetite (Fe3O4) or maghemite (γ-Fe2O3)
nanocrystallites. IONP-biosensors have been developed for the detection of HSV-1 and adenoviruses
enabling to detect five viral particles in 10 µL serum samples without previous PCR amplification
steps [118]. Using IONPs functionalized with IgG [119] and vancomycin [120] have allowed to
push the limit of detection to 104 CFU/mL bacterial cells by using nano-MALDI platforms [121].
Nanodiagnostic systems will allow microbiologists to perform molecular tests faster and with higher
sensitivity. These methods also increase flexibility at reduced costs [122]. However the majority of
these new nanoplatforms still need further evaluation and validation with clinical samples before they
can be fully translated into clinical diagnosis.
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Table 2. Microbiological diagnosis approach by inorganic nanoparticles.
Nanoparticle Based on Detection/Identification by Detection Limit of Detection Ref.
Surface-Enhanced Raman scattering Spectroscopy (SERS)
AgNPs Label-free near infrared surface-enhanced Ramanscattering (NIR-SERS)
Spectrum




Surface-enhanced Raman scattering spectroscopy (SERS)
Legionella spp. [124]
Vancomycin coatted Ag-Au-NPs S. epidermidis, B. megaterium,E. coli & Salmonella enterica 10
2 CFU/mL [125]
Surface Plasmon resonance (SPR). NanoProbes
AuNPs
Differential stabilization of Au-nanoprobes in presence of DNA targets
following salt induced aggregation
Colorimeric detection from
red to blue
TB 0.75 µg 2 h [11]
Different interaction between ssdna and dsdna at the surface of aunps,
based on the aggregation of unmodified aunps Bacillus. anthracis [126]
Cross-linking approach, where the target DNA acts as a linker between
two different Au nanoprobes; based on aunp aggregation
Colorimetric detection from
red to blue MRSA 66 pg/µL (<10
5 CFU/mL) [11]
Interaction aunps–dsdna & the addition of thiolated probes specific to
the inva gene in the Salmonella genomic DNA aggregates aunps
Colorimetric detection from
red to violet S. enterica 37 fM [127]
The ability of ssdna oligo-targeters to stabilize the colloidal aunps
preventing their salt-induced aggregation. Colorimetric detection Acinetobacter baumani 0.8125 ng/µL [128]
Non-cross-linking method results from the differential aggregation
profiles of Au-nanoprobes induced by increased ionic strength in the
presence or absence of the specific target sequence
Colorimetric detection (SPR
band: 525–650 nm)









B. megaterium, E. coli,
P. aeruginosa
[131]
Fast lateral flow immunoassay (FLFI) approach combined with rapid
“one step” lysis Colorimetric detection E. coli 5ˆ 10
4 CFU/mL 25 min [132]
Aptamer-conjugated-AuNPs
aptamer–DNA duplex formed by the hybridization reaction between
the capture probe and the aptamer probe, which induces a clear
enzymatic catalysis of the oxidation of methionine by
hydrogen peroxide
Biosensor C. difficile 1 nM [133]
glassy carbon electrode modified with graphene oxide and AuNPs Electrochemical impedancespectrum Salmonella 3 CFU/mL [134]
cell-based SELEX (Systematic Evolution of Ligands by Exponential




S. aureus 10 CFU/mL 1.5 h [135]
AuNPs paper-paper Non-cross-linking assay wax-printed microplate paper platform Colorimetric detection fromred to blue TB 30 µg/mL 2 h [136]
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Table 2. Cont.
Nanoparticle Based on Detection/Identification by Detection Limit of Detection Ref.
Microarrays
AuNPs Multiple capture and intermediate oligos to detect a target inmultiple regions
Silver signal by scanomatric
detection Influenza Virus H5N1
<105 copies of
transcribed RNA; 2.5 h [137]
Ag-Au core shell NPs Nanoparticle-based microarrays using a photodiode sensor SEM images HPV 0.05 pmol/µL [138]
Magnetic nps
AuMNPs
Non cross-linking aggregation phenomenon: specific interaction
between meca gene with the gold
Colorimetric detection
(λ = 530 nm) MRSA [139]
Electrochemical geno-sensing assay onto the latex microspheres AuNPs signal Vibrio cholerae 2 CFU/mL [140]
Fept@Vanco
Trapping gram-positive bacteria, based on interaction between the
heptapeptide backbone of vancomycin and the D-alanyl-D-alanine
dipeptide from the cell wall
MALDI-TOF Staphylococcus spp., VRE &E. coli 100 CFU/mL [116]
Immunoassay
Au-NPs
AuNPs bound to anti-human IgG
Colorimetric immunoassay
Influenza Virus 10 pg/mL [141]
FLFI combined with ELISA E. coli 0157:H7 103 CFU/mL [142]
Plasmonic ELISA (ELISA with enzyme-mediated SPR of AuNPs) SIFILIS 0.98pg/mL [143]
Ag-NPs SERS enzyme-catalyzed immunoassay RAMAN Intensity SRV 0.05 pg/mL [144]
ELISA, antigen-antibody immunoreaction
Chemiluminescence Salmonella spp. 50–100 CFU/mL [145]
Eu(III)-NPs Fluorescence signal HIV-1 p24 <0.1 pg/mL [146]
AgNPs-G gold electrode coated with AuNPs-G, whose is modified withH7-monoclonal antibodies
Electrochemical
immunosensor Aviar Influenza Virus H7 1.6 pg/mL [147]
FSNPs highly fluorescent bioconjugated nanoparticles probe Fluorescence signal L. monocitogenes 50 CFU/mL [148]
Fluorescence
Si-MNPs high specificity for dsDNA and bright fluorescence upon intercalationinto dsDNA.
Nucleic-acid dye SYBR
Green I signal (Intensity) S. aureus 50 CFU/mL [149]
AgNPs-G: silver nanoparticle-graphene; HPV: Humam Papiloma Virus; FLFI: fast lateral flow immunoassay; MDRTB: Multi Drug resistance TB; MRSA: Methicillin resistan S. aureus;
MTB: multidrug resistant TB; MTBC: Micobacteriun tuberculosis complex; SERS: Surface-enhanced Raman scattering spectroscopy; SPR: Surface Plasmon resonance; SRV: Syncytial
Respiratory Virus; TB: Tuberculosis; VRE: Vancomycyn Resistant Enterococcus spp.
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4. Nanoparticles for Fighting Superbugs
Drug resistance is of a great concern for public health. The use of high dose antibiotic treatments
often generates high rates of toxicity and the development of new resistance. In addition, the costs of
treatments increase while there is a major number of treatment failures and high spectrum therapies
associated with an increase in the number of hospitalization days. Due to the lack of new alternatives
for the treatment of infectious diseases, several classes of antimicrobial nanoparticles and nanocarriers
for antibiotic delivery have been studied, as well as their effectiveness for the treatment of infectious
diseases, including antibiotic resistant bacteria [150].
Nanoparticles provide a versatile platform for the design of materials with antimicrobial
properties. Their unique nanoscale as well as physical and chemical properties provide multiple
attributes that facilitate the development of unique antimicrobial strategies; hence, they are emerging
as weapons in our antimicrobial arsenal. These nano-antimicrobial materials can be synthesized by
variety of different methods influencing subsequent antimicrobial effect [151]. They could be divided
into inorganic, organic and hybrid nanoparticles. The most advantageous are inorganic nanomaterials,
such as Ag and Au, alone or combined with various organic polymers (Figure 1).
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The antimicrobial mechanism of the action of nanoparticles is not fully known. Nevertheless, the
antimicrobial actions include destruction of cell membranes, blockage of enzyme pathways, alterations
of microbial cell wall, and nucleic materials pathway. The applicability of nanoparticles as therapeutic
agents includes a wide range of action, varying from broad spectrum antimicrobial agents, sterilization
and wound healing agents, to sustained inhibitors of intracellular pathogens [152]. The most of the
tested nanoparticles are highly efficient against Staphylococcus aureus and Escherichia coli, and according
to properties they have been even used to treat tuberculosis (TB) [36] (Figure 1).
The antibacterial activity of Ag-nanoparticles is well established, although they face certain
shortcomings due to toxicity to mammalian cells and limited penetration in biofilm matrices [153].
Recent studies [154] have been focused on countering these issues for example by developing Ag
ring-coated super-paramagnetic IONPs (SPIONS) with ligand gaps. This has demonstrated high
antimicrobial activity and remarkable compatibility with healthy host cells, which further exhibited
enhanced activity against biofilm infections due to deeper penetration under an external magnetic
field [155]. Others inorganic nanomaterials such as Au, Cu, Ni, Ti, Zn, graphene-based photo-thermal,
as well as their coupled derivatives, are potential candidate for enhancing or restoring the already
existing antibiotics or new substances to combat the multi-drug-resistance (MDR) problem (Figure 1).
The nanoparticles are indeed potential broad spectrum antibiotics because they can inhibit
a wide range of MDR bacteria which have defied most of antibiotic treatments [152]. For example,
CuO-nanoparticles exert their antibacterial activity by membrane disruption and ROS production [156],
showing an antibacterial efficacy alike to Ag or ZnO. On the other hand, ZnO–nanoparticles, which
are more effective, affect bacterial cell along two pathways: (1) by binding to membranes, disrupting
their potential and integrity, and (2) by inducting ROS production [151]. Hence, ZnO–nanoparticles
inhibit the growth of MSSA, MRSA, MDR or pathogens such as Streptococcus mutans, Lactobacillus,
Klebsiella pneumoniae or E. coli [151], including ESBL producers [157], but also prevent biofilm
formation [158] (Figure 1).
Nanoshuttle systems deliver antibiotics to a precise location and release them progressively in a
controlled manner (shuttle systems). These systems use nanoparticles for the delivery and controlled
released of several antibiotics and natural products. Nanoparticles are free to move uninhibited into
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cells, increasing their efficiency. Antibiotics can be released inside the microorganism, increasing the
therapeutic index and reducing the overall serum concentration. As a result, the deleterious side effects
decrease [159]. An additional advantage is the decrease risk of creating resistance in other commensal
microorganisms [160]. Most applications are focusing on the treatment of osteomyelitis [161], skin
or wound [162] or S. aureus, E. coli or Pseudomonas aeruginosa infections [163]. The antimicrobial
nanomaterials currently in use or under investigation are based on Ag, magnetite, TiO2 and ZnO.
Nanotechnology is also making great progress in combating infections associated with medical devices
(such as those related with biofilms formation), with the implementation of tailored coating systems.
These systems are based on coating the surface with nanoparticles inhibiting biofilm formation. Most
studies have been focused on pathogens frequently associated with nosocomial infections such as
S. aureus, P. aeruginosa, Acinetobacter baumani and K. pneumoniae [160] (Figure 1). Min et al. [164] have
demonstrated the applicability of coated degradable multilayer prosthesis. These coated prosthesis
sequentially deliver the antibiotic and the osteo-inductive growth factor (BMP-2). This coating delivery
system enables both eradication of established biofilms, as well as, a complete and rapid bone tissue
repair around the implant in rats with induced osteomyelitis [164]. Their findings demonstrated the
potential of this layered release strategy. Milo et al. [165] published a novel and previously unreported
application of a pH-responsive polymer, in a dual-layered surface coating for urinary catheters that
provides a visual early warning of Proteus mirabilis infection and their subsequent blockage control.
Nanoparticles keep offering promising alternatives in the design of effective next-generation
therapeutics against bacterial, viral and fungal threats [155]. The perspective of developing powerful
nano-antimicrobial agents with multiple-functionality will revolutionize clinical medicine and it will
play a significant role in alleviating disease burden [152]. Nanoparticle-based antimicrobial agents can
be used in ex vivo applications such as sterilizers for surfaces and devices, and the prospective topical
applications for wound healing of nanoparticles-based systems [155] (Figure 1).
Currently, some drug delivery systems (DDS) usually named “nano-antibiotics” have been
clinically-approved for human use in various infectious diseases, among them, liposomal delivery
systems. Pulmaquin™ and Lipoquin™ (Grifols, S.A., Barcelona, Spain and Aradigm Corporation,
Hayward, CA, USA) are inhalable liposomal dosage forms of ciprofloxacin, for the treatment of
serious infectious diseases encountered in cystic fibrosis (CF) or in non-CF bronchiectasis. AX-Tobra™
(Axentis Pharma, Zurich, Swizerland) based on Fluidosomes® technology and Arikace® (Insmed
Inc., Monmouth Junction, NJ, USA) undergoing phase III clinical trials, are respectively, an inhalable
liposomal tobramycin and amikacin dosage forms, claimed for the treatment of P. aeruginosa pulmonary
infections in cf. [166].
5. Conclusions
Nanobiotechnology offers multiple solutions for the prevention, diagnosis and treatment of
infectious diseases. Nanoparticles can be designed to increase the activity in vaccines with low toxicity
against the host. A huge number of nanoparticles can be used for the delivery and stabilization of
bioactive drugs as well as antimicrobial molecules, ensuring controlled release of the drug. Due to
their specificity, low dimensions, targeted delivery, controlled release properties and low cytotoxicity,
nano-active systems could lead to more efficient and less invasive therapeutic outcome, contributing
to the development of personalized treatment for several infectious diseases.
In the superbug era, nanotechnology is offering a new approach that allows us to fight against
resistant bacteria. Nanobiomedicine offers new tools to be applied in the prevention, detection and
treatment of the infectious diseases, managing to decrease the co-morbidity/mortality ratios, costs and
improving lifestyle quality.
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CFU Colony Forming Unit
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FSNP Fluorescent Silica Nanoparticles
HBV Hepatitis B Virus
HCV Hepatitis C Virus
HIV Human Immunodeficiency Virus
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IONP Iron oxide nanoparticles
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MNP Magnetic nanoparticles
QD Quantum dots
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